{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:13:19Z","timestamp":1777695199900,"version":"3.51.4"},"reference-count":25,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002402","name":"sun yat-sen university","doi-asserted-by":"publisher","award":["2017005"],"award-info":[{"award-number":["2017005"]}],"id":[{"id":"10.13039\/501100002402","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070220"],"award-info":[{"award-number":["82070220"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2021A1515011715"],"award-info":[{"award-number":["2021A1515011715"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Integr Cancer Ther"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Pegylated liposomal doxorubicin (PLD) is highly effective for treating multiple myeloma (MM). Hand-foot syndrome (HFS) is a dose-limiting adverse event of PLD that may reduce a patient\u2019s quality of life or prevent certain patients from receiving PLD. Several researchers have discovered that pyridoxine, an activated form of vitamin B6, may prevent PLD-associated HFS. We designed a prospective randomized trial to examine whether prophylactic pyridoxine might prevent the incidence or delay the occurrence of PLD-induced HFS in patients with MM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Patients who met the trial\u2019s eligibility requirements were randomized and then administered either pyridoxine 100\u2009mg twice daily or no pyridoxine, in both cases accompanied by their PLD-containing chemotherapeutic agent. Follow-up of patients was performed until the completion of induction therapy, the development of HFS or disease progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Between January 1, 2017, and January 1, 2019, 105 patients were randomly assigned to the pyridoxine group (n\u2009=\u200952) or the no pyridoxine group (n\u2009=\u200953). In the pyridoxine and no pyridoxine groups, HFS developed after a median of 4 (range, 1-8 cycles) and 3 (range, 1-7 cycles) chemotherapeutic cycles, respectively. There were no grade 3 incidents recorded. Overall, 13.3% of patients experienced HFS. A 11 of 53 (20.8%) patients in the no pyridoxine group experienced HFS, compared to 3 of 52 (5.8%) patients in the pyridoxine group ( P\u2009=\u2009.042); there was no difference in HFS grades ( P\u2009=\u2009.725).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The findings of benefit from prophylactic pyridoxine in this open-label trial have suggested its promise as a treatment for reducing HFS in MM patients. Further research with a placebo-controlled design is recommended.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration:<\/jats:title>\n                    <jats:p>ChiCTR2100050294.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/15347354221140402","type":"journal-article","created":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:35:37Z","timestamp":1670891737000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Pyridoxine Is Effective for Preventing Hand-Foot Syndrome Induced by Pegylated Liposomal Doxorubicin for Multiple Myeloma: The Results of a Randomized Study"],"prefix":"10.1177","volume":"21","author":[{"given":"Li","family":"Xiaozhe","sequence":"first","affiliation":[{"name":"The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Meilan","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huang","family":"Beihui","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liu","family":"Junru","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gu","family":"Jingli","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuang","family":"Lifen","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0909-4731","authenticated-orcid":false,"given":"Li","family":"Juan","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,12,12]]},"reference":[{"key":"bibr1-15347354221140402","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00135-5"},{"key":"bibr2-15347354221140402","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0b013e32802623fc"},{"key":"bibr3-15347354221140402","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl477"},{"key":"bibr4-15347354221140402","doi-asserted-by":"publisher","DOI":"10.1159\/000327767"},{"key":"bibr5-15347354221140402","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.1807"},{"key":"bibr6-15347354221140402","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2010.07449.x"},{"key":"bibr7-15347354221140402","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-111-8-688"},{"key":"bibr8-15347354221140402","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-009-0171-3"},{"key":"bibr9-15347354221140402","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2016.1238067"},{"key":"bibr10-15347354221140402","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-7563.2010.01326.x"},{"key":"bibr11-15347354221140402","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-7563.2010.01311.x"},{"key":"bibr12-15347354221140402","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-018-4054-z"},{"key":"bibr13-15347354221140402","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2003.s.004"},{"key":"bibr14-15347354221140402","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2019.05.009"},{"key":"bibr15-15347354221140402","doi-asserted-by":"publisher","DOI":"10.12788\/jcso.0017"},{"key":"bibr16-15347354221140402","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200001040-00004"},{"key":"bibr17-15347354221140402","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.01.028"},{"key":"bibr18-15347354221140402","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-017-3781-x"},{"key":"bibr19-15347354221140402","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2002.19505.x"},{"key":"bibr20-15347354221140402","doi-asserted-by":"publisher","DOI":"10.1111\/ced.14486"},{"key":"bibr21-15347354221140402","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejon.2020.101866"},{"key":"bibr22-15347354221140402","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/dd945f7c-c50b-461d-ab38-15e8b0966458","volume":"8","author":"Chen M","year":"2013","journal-title":"PLOS ONE"},{"key":"bibr23-15347354221140402","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25262"},{"key":"bibr24-15347354221140402","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.1269"},{"key":"bibr25-15347354221140402","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08028-8"}],"container-title":["Integrative Cancer Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15347354221140402","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15347354221140402","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15347354221140402","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T09:16:51Z","timestamp":1777454211000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15347354221140402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":25,"alternative-id":["10.1177\/15347354221140402"],"URL":"https:\/\/doi.org\/10.1177\/15347354221140402","relation":{},"ISSN":["1534-7354","1552-695X"],"issn-type":[{"value":"1534-7354","type":"print"},{"value":"1552-695X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"article-number":"15347354221140402"}}